BV650 Rat Anti-Human CD132

due to being discontinued. Suggested alternate SKU is [742573] or for additional support, contact your local applications specialist. Contact us

BD Horizon™ BV650 Rat Anti-Human CD132

Name: BV650 Rat Anti-Human CD132
Brand: BD Horizon™
SKU: 563406

Clone TUGh4

(RUO)

Flow cytometric analysis of CD132 expression on human peripheral blood lymphocytes. Whole blood was stained with either BD Horizon™ BV650 Rat IgG2b, κ Isotype Control (Cat. No. 563233; dashed line histogram) or with BD Horizon™ BV650 Rat Anti-Human CD132 antibody (Cat. No. 563406; solid line histogram). Erythrocytes were lysed with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899). The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometry was performed using a BD™ LSR II Flow Cytometer System.

Spectrum Viewer

Protocol Library

Scientific Resources

Product Details

Brand: BD Horizon™

Alternative Name: IL-2RG; IL-2Rγ; γc; Common γ chain; Common gamma chain; gamma c; SCIDX1

Reactivity: Human (QC Testing), Dog (Tested in Development)

Isotype: Rat IgG2b, κ

Immunogen: Human γc Transfected Cell Line

Application: Flow cytometry (Routinely Tested)

Vol. Per Test: 5 µl

Workshop Number: VI C-89

Entrez Gene ID: 3561

RRID: AB_2738186

Storage Buffer: Aqueous buffered solution containing BSA and ≤0.09% sodium azide.

Regulatory Status: RUO

Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon™ BV650 under optimum conditions, and unconjugated antibody and free BD Horizon™ BV650 were removed.

Recommended Assay Procedures

For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).

Product Notices

This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test).
An isotype control should be used at the same concentration as the antibody of interest.
Source of all serum proteins is from USDA inspected abattoirs located in the United States.
Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
Alexa Fluor® is a registered trademark of Molecular Probes, Inc., Eugene, OR.
For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
Species cross-reactivity detected in product development may not have been confirmed on every format and/or application.
BD Horizon Brilliant Violet 650 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,455,613; 8,575,303; 8,354,239.
BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.

Companion Products

Stain Buffer (FBS) RUO

Size 500 mL Cat No. 554656

Lysing Buffer RUO

Size 100 mL Cat No. 555899

BV650 Rat IgG2b, κ Isotype Control RUO

Size 50 µg Cat No. 563233

563406 Rev. 2

Antibody Details

TUGh4

The TUGh4 monoclonal antibody specifically binds to CD132. CD132 is a 65-70 kDa type 1 transmembrane glycoprotein that is encoded by the IL2RG (interleukin 2 receptor, gamma) gene. CD132 is also known as the common γ subunit (γc) and is shared by the IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 receptor complexes. CD132 is broadly expressed by most peripheral T and B lymphocytes, NK cells, monocytes, and granulocytes. The cytoplasmic domain of the γc chain plays an important role in cytokine-mediated signal transduction. Mutation of the IL2RG gene results in X-linked severe combined immunodeficiency (XSCID). The TUGh4 antibody recognizes a different epitope from that recognized by the CD132-specific clone, AG184.

The antibody was conjugated to BD Horizon BV650 which is part of the BD Horizon Brilliant™ Violet family of dyes. This dye is a tandem fluorochrome of BD Horizon BV421 with an Ex Max of 405-nm and an acceptor dye with an Em Max at 650-nm. BD Horizon BV650 can be excited by the violet laser and detected in a filter used to detect APC-like dyes (eg, 660/20-nm filter). Due to the excitation and emission characteristics of the acceptor dye, there will be spillover into the APC and Alexa Fluor® 700 detectors. However, the spillover can be corrected through compensation as with any other dye combination.

563406 Rev. 2

Format Details

BV650

The BD Horizon Brilliant Violet™ 650 (BV650) Dye is part of the BD Horizon Brilliant Violet™ family of dyes. This tandem fluorochrome is comprised of a BV421 donor with an excitation maximum (Ex Max) of 406-nm and an acceptor dye with an emission maximum (Em Max) at 649-nm. BV650, driven by BD innovation, is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 650-nm (e.g., a 660/20-nm bandpass filter). The acceptor dye can be excited by the Red (628–640-nm) laser resulting in cross-laser excitation and fluorescence spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.

Format: BV650

Excitation Source: Violet 405 nm

Excitation Max: 406 nm

Emission Max: 649 nm

563406 Rev.2

Citations & References

Development References (5)

Ishii N, Kondo M, Takeshita T, and Sugamura K. mAb specific for the γ chain of the IL-2 receptor. In: Schlossman SF. Stuart F. Schlossman .. et al., ed. Leucocyte typing V : white cell differentiation antigens : proceedings of the fifth international workshop and conference held in Boston, USA, 3-7 November, 1993. Oxford: Oxford University Press; 1995:1867-1868.
Ishii N, Takeshita T, Kimura Y, et al. Expression of the IL-2 receptor gamma chain on various populations in human peripheral blood. Int Immunol. 1994; 6(8):1273-1277. (Immunogen: Flow cytometry, Immunoprecipitation, Radioimmunoassay). View Reference
Lin G-X, Yang X, Hollemweguer E, et al. Cross-reactivity of CD antibodies in eight animal species. In: Mason D. David Mason .. et al., ed. Leucocyte typing VII : white cell differentiation antigens : proceedings of the Seventh International Workshop and Conference held in Harrogate, United Kingdom. Oxford: Oxford University Press; 2002:519-523.
Matsuoka M, Takeshita T, Ishii N, Nakamura M, Ohkubo T, Sugamura K. Kinetic study of interleukin-2 binding on the reconstituted interleukin-2 receptor complexes including the human gamma chain. Eur J Immunol. 1993; 23(10):2472-2476. (Biology). View Reference
Tanaka N, Sugamura K. CD132 (interleukin 2 γ chain (common γ) Workshop Panel report. In: Kishimoto T. Tadamitsu Kishimoto .. et al., ed. Leucocyte typing VI : white cell differentiation antigens : proceedings of the sixth international workshop and conference held in Kobe, Japan, 10-14 November 1996. New York: Garland Pub.; 1997:861-864.

View All (5)

563406 Rev. 2

Please refer to Support Documents for Quality Certificates

Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.